Notice of a Shareholder webinar
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Notice of a Shareholder webinar “Funding, execution and path forward”
08 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF)
("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for
neurodegenerative diseases, is pleased to advise it will be hosting a shareholder webinar at 1:00pm AEDT (10:00am
AWST) on Thursday, 15 January 2026.
During the webinar, CEO and Managing Director, Dr. Michael Thurn and other team members will provide an update
on the execution of recent funding initiatives, regulatory developments and pending operational milestones
associated with the HEALEY ALS Platform Trial.
The briefing will be followed by a Q&A session. Questions can be submitted now to enquiries@neurizon.com, during
the registration or in written form during the webinar. Anyone wishing to attend the webinar must register via the
link below.
• Registration: https://bit.ly/15012026
• Date and time: 1:00pm AEDT (10:00am AWST) on Thursday, 15 January 2026
For investors that cannot attend the webinar, a recording will be made available via the Company’s website.
-ENDS-
This announcement has been authorised for release by Michael Thurn, Managing Director and CEO on behalf of the
Board of Neurizon Therapeutics Limited.
For further information, please contact:
Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view
video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
Share your feedback
Discover